Society

LIS Technologies Inc. Establishes Corporate Affiliation with the Nuclear Institute

Retrieved on: 
Friday, April 5, 2024
Uranium, Nuclear, Isotope, Environment, Patent, Science, Engineering, Society, LIS, Science Council, Nuclear Institute, Engineering Council, Bangladesh Technical Education Board, Renewable energy

“It is a pleasure to count ourselves amongst the Nuclear Institute’s Corporate Affiliates,” said Christo Liebenberg, Chief Executive Officer of LIS Technologies Inc. “The Nuclear Institute has long worked towards the advancement of the nuclear industry and the associated technologies.

Key Points: 
  • “It is a pleasure to count ourselves amongst the Nuclear Institute’s Corporate Affiliates,” said Christo Liebenberg, Chief Executive Officer of LIS Technologies Inc. “The Nuclear Institute has long worked towards the advancement of the nuclear industry and the associated technologies.
  • Additionally, through its numerous events, seminars, and volunteer-led activities, the Nuclear Institute ensures a robust platform for professional interaction and development within the nuclear sector.
  • “We are delighted to welcome LIS Technologies Inc as a Corporate Affiliate of the Nuclear Institute,” said Sarah Beacock, Chief Executive Officer of the Nuclear Institute.
  • “As a proprietary developer of patented advanced laser technology based in the US, LIS Technologies are showing their commitment to advancing nuclear science and technology.

Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024

Retrieved on: 
Friday, April 5, 2024
NMIBC, Patient, Mouse, Cancer, Bladder cancer, LIPO, Pembrolizumab, Society, ASCO, Therapy, Physician

Lipella’s abstract, “Intravesical local administration of pembrolizumab for treatment of bladder cancer: A novel strategy to minimize toxicity” will be published at www.asco.org/abstracts .

Key Points: 
  • Lipella’s abstract, “Intravesical local administration of pembrolizumab for treatment of bladder cancer: A novel strategy to minimize toxicity” will be published at www.asco.org/abstracts .
  • Dr. Jonathan Kaufman, Chief Executive Officer of Lipella, said, “ASCO’s 2024 meeting is the ideal venue for dissemination of our recent progress in the treatment of bladder cancer.
  • Lipella’s new product candidate, LP-50 (intravesical pembrolizumab), is intended to be indicated for non-muscle invasive bladder cancer (NMIBC).
  • Dr. Michael Chancellor, Lipella’s Chief Medical Officer, emphasized the significance of this milestone for advancing the company’s LP-50 program.

Nearly Half of High School Students Say Generative AI will Significantly Change the Future Workforce, Global Survey Reveals

Retrieved on: 
Thursday, April 4, 2024
Mathematics, Education, Growth, MathWorks, Data analysis, School, Ethics, Clarkson University, AI, Society, Student, Industrial, Senior, Creativity, Workforce, Computer science and engineering, Media, Workplace, Medical device

The survey polled 825 11th and 12th grade students from across the U.S. and sixth form students in England and Wales to get their insights on the impact of generative AI on their academics and future careers.

Key Points: 
  • The survey polled 825 11th and 12th grade students from across the U.S. and sixth form students in England and Wales to get their insights on the impact of generative AI on their academics and future careers.
  • Nearly half of the students polled expressed some degree of concern about potential loss of jobs in the future workforce due to certain roles becoming automated or obsolete.
  • Only 19% think the AI workforce of the future will deliver greater productivity as people work faster and smarter.
  • How can high schools prepare students for the future world of AI?

Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International

Retrieved on: 
Thursday, April 4, 2024
Homocysteine, Homocystinuria, Caregiver, SAN, HCU, Society, Treatment, Therapy, Genetic, SIMD, Pharmaceutical industry

SAN DIEGO, April 04, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the Company will present eight posters in classical homocystinuria (HCU) at Society for Inherited Metabolic Disorders (SIMD) in Charlotte, North Carolina from April 14-17, 2024, and Genetic Metabolic Dieticians International (GMDI) in Charlotte, North Carolina from April 17-20, 2024.

Key Points: 
  • SAN DIEGO, April 04, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the Company will present eight posters in classical homocystinuria (HCU) at Society for Inherited Metabolic Disorders (SIMD) in Charlotte, North Carolina from April 14-17, 2024, and Genetic Metabolic Dieticians International (GMDI) in Charlotte, North Carolina from April 17-20, 2024.
  • At SIMD and GMDI, the Company will present the trial design of the pivotal Phase 3 HARMONY Study of pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of classical HCU.
  • Additionally, the Company will share insights on the development of an innovative tool used for dietary management and monitoring in the Phase 3 HARMONY Study and open-label extension ENSEMBLE Study, and the positive results from cohort 6 in the placebo-controlled Phase 1/2 COMPOSE Study of pegtibatinase in classical HCU.
  • “Classical HCU is an isolating and devastating rare disorder with very limited treatment options, including adherence to highly restrictive diets, leaving patients and their caregivers with immense challenges,” said Jula Inrig, M.D., chief medical officer of Travere Therapeutics.

RxSight Announces Commercial Launch of its Newest Light Adjustable Lens™, the LAL+™, and Features Multiple Doctor Presentations at the Upcoming ASCRS Annual Meeting

Retrieved on: 
Thursday, April 4, 2024
Level 3, Refractive surgery, ASCRS, BCEC, Patient, Level 2, EDT, Cataract, Society, Lens, LAL, Telescopic sight

The company now offers two lenses in the Light Adjustable Lens platform: the LAL® and the Light Adjustable Lens+™ (LAL+).

Key Points: 
  • The company now offers two lenses in the Light Adjustable Lens platform: the LAL® and the Light Adjustable Lens+™ (LAL+).
  • In addition, RxSight’s Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL/LAL+), RxSight Light Delivery Device (LDD™) and accessories, will be the subject of various doctor presentations at the annual meeting of the American Society of Cataract and Refractive Surgery (ASCRS) in Boston on April 5-8, 2024.
  • At this year's ASCRS meeting, the company anticipates more than 20 scientific papers, posters, and presentations on the topic of the Light Adjustable Lens, including:
    Benefits of Performing Arcuate Incisions with a Dual-Pulsed Femtosecond Laser on Patients Receiving a Light Adjustable Lens.
  • A schedule of these presentations, which are not affiliated with the official ASCRS program, is available here and at the company’s booth throughout ASCRS.

Verana Health Developing Qdata® Dry Eye Disease, the Largest Real-World Dataset of its Kind

Retrieved on: 
Thursday, April 4, 2024
Prevalence, Dry eye syndrome, ASCRS, SAN, Patient, Ophthalmology, Research, RWD, American Academy, Cataract, DED, Society, Data, Telecanthus, Health, Annual general meeting, Nursing

Qdata DED represents a significant advancement in ophthalmology research, and is the largest of its kind, featuring an extensive dataset that will include outcomes and clinical information on more than 10 million de-identified patients with DED and related ocular conditions.

Key Points: 
  • Qdata DED represents a significant advancement in ophthalmology research, and is the largest of its kind, featuring an extensive dataset that will include outcomes and clinical information on more than 10 million de-identified patients with DED and related ocular conditions.
  • “We’re harnessing the power of real-world evidence to transform patient care and expedite the development of crucial therapies,” said Sujay Jadhav, CEO of Verana Health.
  • Dry eye disease affects nearly 16 million Americans , posing significant challenges for patients and ophthalmologists alike.
  • Verana Health remains at the forefront of this transformation, continuously expanding its Qdata offerings to meet the growing needs of life sciences teams and clinicians.

Urology Care Foundation Announces 2024 Research Awards of Distinction

Retrieved on: 
Thursday, April 4, 2024
Western University, Research, American Urological Association, Xenobiotic, Translational research, Postdoctoral researcher, Prostate cancer, Environment, Lawson Health Research Institute, Immunology, Committee, Gut microbiota, University, Macrophage, Doctor of Philosophy, Role, Publication, Pediatrics, University of California, Pediatric urology, Division, FACS, Radiation therapy, Society, Michigan Medicine, Nursing

BALTIMORE, April 04, 2024 (GLOBE NEWSWIRE) -- The Urology Care Foundation, the world’s leading nonprofit urological health foundation and the official foundation of the American Urological Association, is pleased to announce the recipients of the 2024 Research Awards of Distinction.

Key Points: 
  • BALTIMORE, April 04, 2024 (GLOBE NEWSWIRE) -- The Urology Care Foundation, the world’s leading nonprofit urological health foundation and the official foundation of the American Urological Association, is pleased to announce the recipients of the 2024 Research Awards of Distinction.
  • "We are optimistic about the future of urologic research with the selection of the recipients of this year’s Urology Care Foundation Research Awards,” said Harris M. Nagler, MD, Urology Care Foundation President.
  • “We are thrilled with the Urology Care Foundation Research Awards of Distinction awardees this year,” said Steven Kaplan, MD, Chair of the AUA’s Research Council.
  • The awardees will be celebrated at the Urology Care Foundation Research Honors Program held at the AUA Annual Meeting in May 2024.

Biognosys and Alamar Biosciences Forge Strategic Partnership in Proteomics to Advance Biopharma and Precision Medicine Research

Retrieved on: 
Thursday, April 4, 2024
Plasma, NSCLC, Disease, Partnership, Inflammation, Patient, Biomarker, Research, Acquisition, Protein, Proteomics, Biology, Medicine, AACR, Chemokine, Society, Cytokine, Mass spectrometry, Fluid mechanics, Proteome, Annual general meeting, Pharmaceutical industry

This collaboration brings together Biognosys’ expertise in unbiased discovery through data independent acquisition mass spectrometry (DIA-MS) and Alamar’s cutting-edge immunoassays.

Key Points: 
  • This collaboration brings together Biognosys’ expertise in unbiased discovery through data independent acquisition mass spectrometry (DIA-MS) and Alamar’s cutting-edge immunoassays.
  • Building upon this successful proof-of-concept study, Biognosys and Alamar are planning to further collaborate both commercially and scientifically as part of their strategic partnership.
  • Research Collaboration: Biognosys and Alamar will embark on a joint research initiative to explore plasma biology.
  • Oliver Rinner, Ph.D., Founder and CEO of Biognosys, expressed enthusiasm about the collaboration: “We are excited to join forces with Alamar to advance proteomics research.

MacroGenics Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future Disclosures

Retrieved on: 
Wednesday, April 3, 2024
Docetaxel, Prostate cancer, ECOG, B7-H3, Patient, Cancer, Autumn, Society, Safety, ASCO, Therapy, PFS, ADC, Annual general meeting, Pharmaceutical industry

As previously disclosed, safety data from the Company’s ongoing TAMARACK Phase 2 study was submitted in early February to the American Society of Clinical Oncology (ASCO) for presentation at the upcoming Annual Meeting that begins May 31.

Key Points: 
  • As previously disclosed, safety data from the Company’s ongoing TAMARACK Phase 2 study was submitted in early February to the American Society of Clinical Oncology (ASCO) for presentation at the upcoming Annual Meeting that begins May 31.
  • The abstract containing this early interim data, based on a January 4, 2024 data cut-off, was not accepted.
  • TAMARACK is an ongoing randomized, open-label, Phase 2 dose selection study assessing the efficacy, safety, and tolerability of two dose levels of vobra duo (2.0 mg/kg and 2.7 mg/kg IV Q4W).
  • At data cutoff (Jan 4, 2024), 182 pts with mCRPC enrolled on TAMARACK, of which 177 received vobra duo.

Eyenovia to Feature its Suite of Commercial Products and the Optejet Dispenser at Upcoming National Eyecare Meetings

Retrieved on: 
Wednesday, April 3, 2024
Clobetasol, Exchange, Infection, Acceleration, Refractive surgery, Inflammation, Annual general meeting, ASCRS, Patient, Private practice, Cataract, Society, Ophthalmology

NEW YORK, April 03, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic company, today announced that the company will be conducting demonstrations of its portfolio of commercial products at two upcoming ophthalmology medical meetings.

Key Points: 
  • “Our presence at national medical and commercial meetings like these are key to elevating awareness of our continuum of office-based and surgical products,” stated Michael Rowe, Eyenovia’s Chief Executive Officer.
  • These meetings complement the efforts of our field sales force in amplifying the synergistic nature of our product portfolio as well as the many benefits conferred to doctors and patients by the Optejet device.
  • Eyenovia will also be demonstrating Avenova and reviewing now-approved data on clobetasol, which complements the company’s surgical suite of products.
  • The event features continuing education, keynote speakers, Exchange-only pricing from more than 100 vendors, and opportunities to network with colleagues.